Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker

Exclusion Criteria

• •1. Patients with other urinary system malformations or serious diseases (such as hypospadias, cryptorchidism, posterior urethral valvular disease, vesicoureteral reflux, neurogenic bladder, urinary system tumors, urinary calculi, bladder and urethral injuries, etc.);
• •2. complicated with neurological diseases (such as epilepsy, spinal cord injury, spinal cord dysplasia, tethered cord syndrome, multiple sclerosis, autism spectrum disorder, etc.);
• •3. Patients with severe heart disease, abnormal liver and kidney function, lung disease, bone malformation, severe digestive tract disease, and genetic metabolic disease;
• •4. History of gastrointestinal surgery and urinary system surgery;
• •5. Dry stool, long-term constipation;
• •6. are taking anticonvulsant and antiepileptic drugs, hormones, antituberculosis drugs;
• •7. Previous history of hypercalcemia, hyperphosphatemia with renal rickets;
• •8. History of unexplained hematuria and urinary tract infection in the past 1 year;
• •9. Have a history of allergy or allergic reaction to vitamin D preparations;
• •10. Participating in another clinical study at the time of visit or during the follow-up of another clinical study;
• •11. Those who did not want to participate in the study or had poor follow-up compliance